膀胱内灌注化疗与全身化疗在浅表性膀胱癌治疗中的应用
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.
作者信息
Soloway M S
出版信息
Urol Clin North Am. 1984 Nov;11(4):623-35.
PMID:6438857
Abstract
Before deciding to begin intravesical prophylaxis, the physician must categorize the patient with respect to the stage of the tumor and the multiplicity of lesions. This may require mucosal biopsies in order to determine whether the patient had unifocal or multifocal disease. Thiotepa, mitomycin C, and doxorubicin hydrochloride are discussed specifically and compared.
摘要
在决定开始膀胱内预防治疗之前，医生必须根据肿瘤分期和病变的多发性对患者进行分类。这可能需要进行黏膜活检，以确定患者患有单灶性还是多灶性疾病。文中具体讨论并比较了噻替派、丝裂霉素C和盐酸阿霉素。
相似文献
1
Intravesical and systemic chemotherapy in the management of superficial bladder cancer.膀胱内灌注化疗与全身化疗在浅表性膀胱癌治疗中的应用
Urol Clin North Am. 1984 Nov;11(4):623-35.
2
Rationale for intravesical chemotherapy in the treatment and prophylaxis of superficial transitional cell carcinoma.膀胱内化疗在浅表性移行细胞癌治疗和预防中的原理。
Prog Clin Biol Res. 1989;310:215-36.
3
[Possibilities and value of intracavitary and systemic chemotherapy of bladder cancer].
Z Urol Nephrol. 1982 Dec;75(12):889-95.
4
[Progress in the internist treatment of bladder tumors].
Wien Med Wochenschr. 1982 Jul 31;132(13-14):305-12.
5
Surgery and intravesical chemotherapy in the management of superficial bladder cancer.
Semin Urol. 1983 Feb;1(1):23-33.
6
[Intravesical chemotherapy in superficial tumors of the bladder].
Arch Esp Urol. 1983 Jan-Feb;36(1):32-40.
7
Intravesical chemotherapy in the management of superficial bladder tumors.
Prog Clin Biol Res. 1984;153:275-85.
8
Intravesical therapy for bladder cancer.膀胱癌的膀胱内治疗
Urol Clin North Am. 1988 Nov;15(4):661-9.
9
10
Systemic therapy of bladder cancer.膀胱癌的全身治疗。
Prog Clin Biol Res. 1984;162B:95-105.
引用本文的文献
1
Clinical significance of nuclear p53 protein accumulation in bladder cancer.核p53蛋白在膀胱癌中积累的临床意义
Int Urol Nephrol. 1999;31(3):327-34. doi: 10.1023/a:1007122118882.
2
Intravesical administration of tumor-associated monoclonal antibody AUA1 in transitional cell carcinoma of the bladder: a study of biodistribution.
Urol Res. 1993;21(6):435-8. doi: 10.1007/BF00300082.
3
Treatment of bladder carcinoma in situ with mitomycin C: long-term follow-up.
Int Urol Nephrol. 1994;26(4):437-42. doi: 10.1007/BF02768015.
4
A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.表柔比星预防性膀胱内化疗治疗浅表性膀胱癌的II期研究。东京女子医科大学膀胱癌协作组。
Cancer Chemother Pharmacol. 1994;35 Suppl:S60-4. doi: 10.1007/BF00686922.
5
Selection of patients for intravesical therapy for superficial bladder cancer.
Int Urol Nephrol. 1994;26(5):523-8. doi: 10.1007/BF02767653.
6
Inhibition of bladder tumor cell implantation in cauterized urothelium, without inhibition of healing, by a fibronectin-related peptide (GRGDS).通过一种纤连蛋白相关肽（GRGDS）抑制膀胱肿瘤细胞在烧灼的尿路上皮中的植入，同时不抑制愈合。
Ann Surg Oncol. 1995 Sep;2(5):450-6. doi: 10.1007/BF02306380.
Zotero 插件